Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography.

MLA

Bauer, Martin, et al. “Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography.” Clinical Pharmacology and Therapeutics, vol. 104, no. 1, July 2018, pp. 139–47. EBSCOhost, https://doi.org/10.1002/cpt.888.

APA

Bauer, M., Matsuda, A., Wulkersdorfer, B., Philippe, C., Traxl, A., Özvegy-Laczka, C., Stanek, J., Nics, L., Klebermass, E.-M., Poschner, S., Jäger, W., Patik, I., Bakos, É., Szakács, G., Wadsak, W., Hacker, M., Zeitlinger, M., & Langer, O. (2018). Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. Clinical Pharmacology and Therapeutics, 104(1), 139–147. https://doi.org/10.1002/cpt.888

Chicago

Bauer, Martin, Akihiro Matsuda, Beatrix Wulkersdorfer, Cécile Philippe, Alexander Traxl, Csilla Özvegy-Laczka, Johann Stanek, et al. 2018. “Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography.” Clinical Pharmacology and Therapeutics 104 (1): 139–47. doi:10.1002/cpt.888.